Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma

Immune Response to 3 Approaches Clinical Trial

Official title:

Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03409224
• Other study ID #: 2009-6735
• Status: Terminated
• Start date: January 2003
• Est. completion date: April 2019

Study information

• Verified date: April 2021
• Source: University of California, Irvine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to compare changes in the body's self-defense (immune response) after two different treatments for small kidney tumors: 1) Cryoablation (freezing) therapy in which the tumor and a margin of normal kidney tissue are frozen and thawed twice with a needle probe and 2) radiofrequency ablation (RFA) in which radiofrequency energy delivered through a needle probe is used to heat tissue and thereby destroy a tumor.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 53
• Est. completion date: April 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• You are eligible to participate in this study if you are an adult (older than 18 years)

• Diagnosed with renal cell cancer 1-3 centimeters in size on the CT scan.

Exclusion Criteria:

• You are not eligible to participate in this study if you are immune compromised (chemotherapy,corticosteroid use, HIV [as documented in your medical record], etc.)

• Have an autoimmune disorders (Rheumatoid arthritis, Crohn's disease, etc)

• Have a tumor larger than 4 cm

• Are pregnant.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Immune Response to 3 Approaches

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Irvine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immune Response to Cryoablation, RFA and Laparoscopic Partial Nephrectomy	The number of leukocytes found in the tissues cryoablation, radiofrequency ablation, or laparoscopic partial nephrectomy (control)	4 years